80137-edited.docx

Retrospective Cohort Study

The effect of prolonged chemotherapy cycles on the prognosis of patients with Stage II and III gastric cancer after D2+ gastrectomy

Li Y *et al*. Excessive chemotherapy cycles after D2 gastrectomy

Yifan Li, Wenbin Zhang, Yuye Gao

Abstract

BACKGROUND

According to relevant investigation and analysis, there are few literatures on the effect of excessive chemotherapy cycles after D2 gastrectomy on the survival of patients with gastric cancer.

AIM

To determine whether excessive chemotherapy cycles provide extra survival benefits, reduce recurrence rate, and improve survival rate in patients with stage II or III gastric cancer.

METHODS

We analyzed and summarized 412 patients with stage II gastric cancer and 902 patients with stage III gastric cancer who received D2 gastrectomy plus adjuvant chemotherapy or neoadjuvant chemotherapy. Analysis and comparison at a ratio of

1:1 is aimed at reducing realistic baseline differences (n = 97 in each group of stage II, n = 242 in each group of stage III). Progression-free survival, overall survival and recurrence were the main outcome indicators.

RESULTS

When the propensity score was matched, the baseline features of stage II and III gastric cancer patients were similar between the two groups. After a series of investigations, Kaplan-Meier found that the progression-free survival and overall survival of stage II and III gastric cancer patients were consistent between the two groups. The local metastasis rate (P = 0.002), total recurrence rate (P < 0.001) and distant metastasis rate (P = 0.001) in the ≥ 9 cycle group of stage III gastric cancer were statistically lower than those in the < 9 cycle group. The interaction analysis by Cox proportional hazard regression model showed that intestinal type, proximal gastrectomy, and ≥ 6 cm maximum diameter of tumor had a higher risk of total mortality in the < 9 cycles group.

CONCLUSION

Overall, ≥ 9 chemotherapy cycles is not recommended for patients with stage II and stage III gastric cancer because it has an insignificant role in the prognosis of gastric cancer. However, for patients with stage III gastric cancer, ≥ 9 cycles of chemotherapy was shown to significantly decrease recurrence.

Key Words: Gastric cancer; Propensity score matching; Chemotherapy cycles; Overall survival; Progression-free survival; Recurrence

Li Y, Zhang W, Gao Y. Prognostic effect of excessive chemotherapy cycles for stage II and III gastric cancer patients after D2+gastrectomy. *World J Gastrointest Surg* 2022;

Core Tip: This retrospective study determined the survival benefit of excess chemotherapy cycles for gastric cancer after D2 gastrectomy. No difference in

progression-free survival and overall survival was observed between patients receiving ≥ 9 or < 9 cycles of chemotherapy. Stage III gastric patients receiving ≥ 9 cycles of chemotherapy had significantly lower overall recurrence, local-regional metastasis, and distant metastasis. Cox proportional risk regression model was used in the exploration and analysis that intestinal type, proximal gastrectomy, and ≥ 6 cm maximum tumor diameter had a higher risk of total mortality in the < 9 cycles of chemotherapy group.

INTRODUCTION

Common cancer cases in the world include gastric cancer, which is also the main cause of human cancer death[1]. Specifically, gastric cancer, one of the most common cancers in the world, has a survival rate of only 20%. Stomach cancer is a malignant tumor in which cancer cells attach to the gastric mucosa and gradually spread throughout the body. At the beginning, there is no special condition of gastric cancer, which can not be seen by ordinary people. However, with the extension of time and the deterioration of the disease, people's stomachs are gradually unable to digest, causing discomfort. In the final period, gastric cancer patients will vomit, pain, and in severe cases will cough up blood, and appear abdominal swelling, lymph node metastasis and so on. According to the relevant data, the production of gastric cancer is affected by different factors, the initial may be chronic gastritis, or bacterial infection, or the gastrointestinal discomfort caused by genes and adverse environment, which may turn into gastric cancer. Among them, the most important factor affecting the occurrence of gastric cancer is the bad environment. If the soil or water contains excessive nitrate and other chemical elements, it is very likely to lead to the occurrence of gastric cancer, and people will inevitably ingest these elements during the diet. In daily life, salty food can also lead to stomach cancer. Moldy food can also cause stomach cancer if consumed for a long time. Generally speaking, the incidence of gastric cancer in women is much lower than that in men, and the most important type of gastric cancer is adenocarcinoma, including diffuse gastric cancer and intestinal

gastric cancer. The older people are, the more likely they are to develop stomach cancer, ranging in age from 50 to 80. The incidence of stomach cancer of our people is not low in the global scope, and is far higher than the world average level. Stomach cancer accounts for nearly a quarter of cancer deaths. In the early stage of gastric cancer, when there is no lymphatic metastasis, endoscopic treatment is recommended. In the middle stage of gastric cancer, when the cancer cells are not spreading throughout the body, it can be treated by surgery, usually D2 gastrectomy. After the tumor is removed, adjuvant therapy is given postoperatively to reduce the likelihood of bacterial infection and avoid the risk of death.

Although D2 gastrectomy and postoperative adjuvant therapy are the only radical methods for the treatment of gastric cancer at this stage, patients with stage II and III gastric cancer have a higher recurrence rate after surgery and do not have a higher long-term survival rate. In academia, experts and scholars have discussed the value and effect of postoperative adjuvant chemotherapy for gastric cancer. With the development of The Times and the progress of society, more and more people analyze the influence of postoperative adjuvant therapy on gastric cancer patients through experiments and research contents. In this context, people increasingly affirm the value of postoperative adjuvant chemotherapy for gastric cancer. According to relevant data, postoperative adjuvant chemotherapy reduced the mortality rate by more than 20% compared with surgery alone. Therefore, the comprehensive treatment mode of surgery combined with adjuvant chemotherapy has been used more frequently in the treatment of gastric cancer. However, at present, the duration of adjuvant therapy after radical gastrectomy has not been determined, and the correlation between the length of chemotherapy cycle and the effect of chemotherapy is not clear. In other words, with the development of The Times, D2 gastrectomy [2] and subsequent adjuvant chemotherapy are constantly improved, and the overall survival period (OS) of gastric cancer patients has been well transformed, but from the perspective of long-term survival, there are still limitations [3,4].

Excessive chemotherapy cycles to treat gastric cancer has been proposed, but the

survival benefit has not been determined. According to the Chinese Society of Clinical Oncology (CSCO) clinical guidelines[5] for the diagnosis and treatment of gastric cancer, preoperative neoadjuvant chemotherapy is recommended for 2-4 cycles, and perioperative neoadjuvant chemotherapy is recommended for 2-4 cycles before surgery and 6-8 cycles after surgery. Therefore, ≥ 9 cycles of chemotherapy would be considered as excessive chemotherapy cycles.

In our previous study[18] of patients with stage II and stage III gastric cancer, the mean of chemotherapy cycles was 9.65 ± 3.86 and 9.87 ± 3.84, respectively. In addition, we analyzed 1 -, 3 - and 5-year survival rates for patients receiving < 9 cycles of chemotherapy were 92.4% (257/278), 66.9%(186/278), and 46.4%(129/278), respectively. The 1-, 3-, and 5-year survival rates for patients receiving ≥ 9 cycles of chemotherapy were 92.5%(577/624), 62.9%(393/624), and 46.3%(289/624), respectively.

In essence, chemotherapy can be both good and bad for patients. Excessive chemotherapy cycles (≥ 9) give rise to unpleasant side effects and harmful effects on physical function. However, the appropriate number of chemotherapy cycles may eliminate any residual cancer cells. The ultimate aim of our research was to determine whether excessive chemotherapy cycles (≥ 9) increase survival and decrease recurrence in patients with stage II and III gastric cancer.

MATERIALS AND METHODS

Data collection

We summarized the relevant data from 2002 to 2020，more than 400 patients with stage II gastric cancer and 900 patients with stage III gastric cancer underwent gastrectomy for treatment of gastric cancer. According to the data, lymph node dissection was higher than D2(complete removal of group 1 and group 2 lymph nodes). The clinicopathological characteristics included age of surgery, sex, nerve invasion, vascular invasion, number of positive lymph nodes, depth of tumor invasion, number of chemotherapy cycles, TNM stage (according to the 8th edition of

the American Joint Board on Cancer), maximum tumor diameter, Lauren classification, retinal metastasis, type of gastrectomy, chemotherapy administration, surgical margin, multi-organ resection, chemotherapy protocol, and group Clavien-Dindo grading of texture, multiple metastases, OS, complications, progression-free survival (PFS). The number of postoperative chemotherapy cycles, the number of neoadjuvant chemotherapy cycles, medical records, surgical records and follow-up data were analyzed retrospectively.

The inclusion criteria consisted of: (1) Neoadjuvant chemotherapy or adjuvant chemotherapy before radical gastrectomy; (2) Histologically proven gastric cancer; (3) There was no serious damage to the organs after the operation; (4) Complete clinicopathological and follow-up data; (5) Except for gastric cancer, there were no other malignancies or causes of death. Exclusion criteria are classified as follows :(1) There is no complete clinical data; (2) other systemic tumors; (3) Non-gastric cancer was confirmed by pathological classification; (4) Bypass surgery and palliative surgery.

The American Joint Board on Cancer's 8 TNM grade reclassifies tumor stages. Because this study is retrospective, consent is not required. After a series of reviews, the Ethics Committee of Shanxi Cancer Hospital finally approved the study. This study was consistent with the standards of the Declaration of Helsinki, so patient anonymity was adopted and patient data and information were not disclosed to the public. The specific research content and process are shown in the figure below (Figure 1).

Patients received individualized chemotherapy regimens. This paper summarized the dose ranges and other details of several common regimens :(1) oxaliplatin (130 mg/m²), S-1 and oxaliplatin (SOX), S-1 (40-60 mg), the above-mentioned drugs twice a day, the 1st to 14th day, rest for 7 days; (2) Gemelacil/Tegafur/Oataxil (S-1), the aforementioned drug twice daily, with the specific dose schedule determined by the patient's area. From day 1 to day 14, 40-60 mg, then rest for 7 days; (3) S-1 + apatinib, apatinib (500 mg) administered once daily

continuously and S-1 (40-60 mg) administered twice daily on day 1 to day 14, then rest for 7 days; (4) Folinic acid, fluorouracil, and oxaliplatin (FOLFOX), folinic acid (200 mg/m²), fluorouracil (2800 mg/m²), and oxaliplatin (85 mg/m²) administered every 3 wk; (5) Oxaliplatin and capecitabine (also known as XELOX) were given intravenous oxaliplatin (150 mg/m²) on the first day of every three cycles and orally capecitabine (1000 mg/m²) twice a day from day 1 to day 14, followed by a rest for 7 days; (6) Capecitabine was taken orally twice a day (1000 mg/m²), with a rest of 7 days from day 1 to day 14; (7) Cisplatin and fluorouracil (also known as DCF), S-1 + docetaxel, cisplatin (75 mg/m²), docetaxel (75 mg/m²) on day 1 to day 5, fluorouracil (750 mg/m²) on day 1 to day 5, S-1 (40-60 mg) on day 1 to day 14, orally twice a day, then rest for 7 days; (8) Oral administration of defluoruridine (1000 mg/m²) twice a day from day 1 to day 28, followed by rest for 14 days.

All excised specimens were examined to determine the histological response to neoadjuvant chemotherapy and pathological staging. The number of surviving tumor cells in the tumor determines the grade of tumor regression. According to Ryan criteria[6]: Grade 0 (complete response), no residual tumor cells. Grade 1 (primary remission), with scattered tumor cells; Grade 2 (moderate remission), tumor cell aggregation with fibrosis; Grade 3 (mild remission), with substantial tumor cell retention. The toxicity associated with neoadjuvant chemotherapy was evaluated according to Standard 5.0, a common term for adverse events[7].

Follow-up

Patients were followed up until December 2020. The second-stage follow-up was 41.51±21.18 months, and the third-stage follow-up was 43.56±24.45 months. Follow-up was conducted every 3 months for 1 year after surgery, every 6 months for 2 to 5 years, and annually thereafter. Routine follow-up included laboratory tests, physical examinations, pelvic ultrasound, chest radiographs, magnetic resonance imaging, and computed tomography.

Statistical analyses

Sex, age at surgery, vascular invasion, nerve invasion, depth of tumor invasion, number of positive lymph nodes, Lauren classification, maximum tumor diameter, type of gastrectomy, and HER2 status were used for propensity score matching (PSM) using 1:1 nearest neighborhood with no replacement and calipers adjusted for sample size and matching success. If a patient is a match, a correlation analysis of primary and secondary endpoints will be performed. The main contents are PFS and OS. The secondary endpoints were tumor recurrence and metastasis, multiple metastases, and recurrence patterns.

Each group generated a Kaplan-Meier survival curve using a log-rank comparison. The category variable analysis was tested using appropriate tests. The P values on both sides were 0.05, which had statistical value. The date of return visit is calculated from the date of surgery to the time of last contact. OS is the time between surgery and death or the last follow-up. PFS refers to the time between surgery and the first recorded death or recurrence.

All data were analyzed and explored using SPSS25.0 software (IBM, Armonk, NY, United States). The classification variable was expressed as percentage, and the test methods used in the analysis were Fisher's exact test and Chi-square test. Continuous data were expressed as mean $\pm$ standard deviation, and T-test was used for analysis. Survival analysis of PFS and OS was performed using Kaplan-Meier method, which was compared with the log-rank test method. Median was used for the non-normal distribution parameters, and the analysis method was Mann-Whitney test. Subgroup analyses were performed by the Cox hazard regression model. $P < 0.05$ was considered statistically significant. PSM was performed with the Hansen and Bowers overall balance test. Relative multivariate imbalance L1 test was used to determine standardized mean difference < 0.25. The χ^2 test was used to compare the differences in recurrence, local-regional recurrence, peritoneal metastasis, and distant metastasis between the two groups.

RESULTS

PSM and subgroup analysis of TNM stage II gastric cancer patients

Patients in the < 9 cycles group received the following chemotherapy regimens: (1) 1 patient received S-1; (2) 28 patients received SOX; (3) 4 patients received S-1 + docetaxel; (4) 10 patients received deofuridine; (5) 3 patients received XELOX; (6) 32 patients received FOLFOX; and (7) 18 patients received multiple regimen combinations. Patients in the ≥ 9 cycles group received the following chemotherapy regimens: (1) 61 patients received S-1; (2) 6 patients received SOX; (3) 9 patients received S-1 + apatinib; (4) 15 patients received capecitabine; (5) 2 patients received FOLFOX; and (6) 5 patients received multiple regimen combinations. Three patients in the < 9 cycles group and 21 patients in the ≥ 9 cycles group received neoadjuvant chemotherapy plus adjuvant chemotherapy. Ninety-four patients in the < 9 cycles group and 76 patients in the ≥ 9 cycles group received only postoperative adjuvant chemotherapy.

All patients with TNM stage II (n = 412) were grouped based on nine variables (sex, vascular invasion, nerve invasion, number of positive lymph nodes, depth of tumor invasion, maximum tumor diameter, Lauren classification, type of gastrectomy, and HER2 status) according to the cycles of chemotherapy received (< 9 cycles vs ≥ 9 cycles) (Table 1). Significant differences in sex (P = 0.022) and age (P < 0.001) were observed between the < 9 cycles group vs the ≥ 9 cycles group before PSM. However, after PSM, in which 194 patients were included (97 patients in the <9 cycles group and 97 patients in ≥ 9 cycles group), no significant differences were observed between the two groups (P > 0.05). The Hansen and Bowers overall balance test indicated that the distribution between the two groups was well balanced after PSM (Figures 2 and 3).

OS and PFS were similar in both groups before and after PSM (P > 0.05), indicating that in patients with stage II gastric cancer ≥ 9 chemotherapy cycles does not impart a survival benefit (Figures 2 and 3). In detail, the 1-year OS rate (96.9% vs 97.9%, log-rank P = 0.650), 3-year OS rate (89.7% vs 89.7%, log-rank P = 1.000), and 5-year OS rate (79.4% vs 83.5%, log-rank P = 0.460) were not statistically different. The 1-year PFS rate was statistically different between the ≥ 9 cycles group and the < 9 cycles group

(93.8% *vs* 82.4%, log-rank *P* = 0.015, respectively). However, that benefit was not observed in the 3-year PFS rate (76.3% *vs* 81.4%, log-rank P = 0.379) and in the 5-year PFS rate (69.1% *vs* 77.3%, log-rank P = 0.195). No differences were observed between the < 9 cycles group and the ≥ 9 cycles group for recurrence (22.7% *vs* 12.4%, respectively, *P* = 0.059), local-regional metastasis (11.3% *vs* 11.3%, respectively, *P* = 0.117), and distant metastasis (5.2% *vs* 6.2%, respectively, *P* = 0.204).

We performed subgroup analyses according to depth of tumor invasion, sex, vascular invasion, number of positive lymph nodes, Lauren classification, neural invasion, types of gastrectomy, maximum diameter of tumor, and HER2 in order to determine if a survival benefit of ≥ 9 cycles was evident in specific patient populations. After subgroup analysis, the differences in OS and PFS between the two groups were not statistically significant (Table 2, Table 3, and Figure 3).

PSM and subgroup analysis of TNM stage III gastric cancer patients

Patients in the < 9 cycles group received the following chemotherapy regimens: (1) 5 patients received S-1 + apatinib; (2) 4 patients received S-1 + DCF; (3) 10 patients received SOX + FOLFOX; (4) 4 patients received S-1 + FOLFOX; (5) 8 patients received XELOX; (6) 98 patients received FOLFOX; and (7) 18 patients received multiple regimen combinations. Patients in the ≥ 9 cycles group received the following chemotherapy regimens: (1) 142 patients received S-1; (2) 2 patients received SOX; (3) 2 patients received S-1 + DCF; (4) 29 patients received capecitabine; (5) 9 patients received doxifluridine; (6) 6 patients received SOX + FOLFOX; (7) 2 patients received FOLFOX; and (8) 50 patients received multiple regimen combinations. Twenty-four patients in the < 9 cycles group and forty-one patients in the ≥ 9 cycles group received neoadjuvant chemotherapy plus adjuvant chemotherapy. Two hundred eighteen patients in the < 9 cycles group and two hundred and one patients in the ≥ 9 cycles group received only postoperative adjuvant chemotherapy.

All patients with TNM stage III (*n* = 902) were grouped based on nine variables (sex, vascular invasion, nerve invasion, number of positive lymph nodes, depth of

tumor invasion, maximum tumor diameter, Lauren classification, type of gastrectomy, and HER2 status) according to the cycles of chemotherapy received (< 9 cycles *vs* ≥ 9 cycles). Significant differences in age (P < 0.001) and type of gastrectomy (P = 0.044) were observed between the < 9 cycles group and the ≥ 9 cycles group before PSM. After PSM, in which 484 patients were included (there were 242 patients in the ≥ 9 cycle group and 242 patients in the < 9 cycle group), differences were observed between variables in the two groups (P > 0.05). The Hansen and Bowers overall balance test indicated that the distribution between the two groups was well balanced after PSM (Figures 4 and 5).

OS and PFS were similar in both groups before and after PSM (P > 0.05), indicating that in patients with stage III gastric cancer ≥ 9 chemotherapy cycles does not impart a survival benefit (Figures 2 and 3). In detail, the 1-year OS rate (91.7% vs 92.5%, log-rank P = 0.735), 3-year OS rate (67.4% vs 63.6%, log-rank P = 0.389), and 5-year OS rate (47.1% *vs* 42.5%, log-rank *P* = 0.315) were not statistically different. The 1-year and 3-year PFS rates in the ≥ 9 period group and the <9 period group were statistically significant (80.1% *vs* 62.0%, log-rank *P* < 0.001, respectively, and 44.2% vs 54.5%, log-rank P = 0.023, respectively). However, that benefit was not observed in the 5-year PFS rate (38.4% vs 33.9%, log-rank P = 0.298). We observed that ≥ 9 chemotherapy cycles can significantly reduce the probability of recurrence compared to < 9 chemotherapy cycles (24.4% vs 48.8%, respectively, P < 0.001), local-regional metastasis (10.7% vs 21.1%, respectively, P = 0.002), and distant metastasis (12.4% vs 24.0%, respectively, *P* = 0.001) but not peritoneal metastasis (1.2% *vs* 3.7%, respectively, *P* = 0.090).

We performed subgroup analyses according to depth of tumor invasion, sex, vascular invasion, neural invasion, number of positive lymph nodes, maximum diameter of tumor, Lauren classification, types of gastrectomy, and HER2 in order to determine if a survival benefit of ≥ 9 cycles was evident in specific patient populations. The analyses demonstrated that the ≥ 9 chemotherapy cycles group had increased OS compared to the < 9 chemotherapy cycles for most subgroups (Table 5). Significant

interactions were observed between chemotherapy cycles and the number of positive lymph nodes (*P* for interaction = 0.007), Lauren classification (*P* for interaction = 0.002), type of gastrectomy (*P* for interaction = 0.004), and maximum tumor diameter (*P* for interaction < 0.001).

After further interaction subgroup analyses, patients with ≤ 6 positive lymph nodes [hazard ratio (HR): 1.312, 95% confidence interval (CI): 0.867-1.988], with intestinal type (HR: 1.196, 95%CI: 0.873-1.640), receiving proximal gastrectomy (HR: 1.175, 95%CI: 0.680-2.032), with ≥ 6 cm maximum diameter of tumor (HR: 1.240, 95%CI: 0.909-1.692) showing a higher risk of total mortality in the < 9 cycles group compared with the ≥ 9 cycles group.

DISCUSSION

According to relevant data, the literature shows that the number of chemotherapy cycles received by patients is associated with the prognosis. A study conducted in China showed that patients with triple-negative breast cancer who received at least four chemotherapy cycles had a significantly better survival rate[8]. Another study in China focused on the link between the number of chemotherapy cycles and the survival rate of patients with bone-only metastasis[9]. Survival factors and prognostic factors of nasopharyngeal carcinoma patients were explored and analyzed, and the conclusion was drawn that the influencing factors of OS included the number of chemotherapy cycles and the number of metastatic sites. An investigation in Australia showed that the survival rate and pathological response rates of patients with muscle invasive bladder cancer were better in patients receiving 4 cycles of neoadjuvant chemotherapy compared to patients receiving 3 cycles of neoadjuvant chemotherapy[10]. A study in China observed that the optimal number of adjuvant chemotherapy cycles for colon cancer patients is often less than 5[11]. The 5-year survival rate of locally advanced rectal cancer treated with chemotherapy was higher than that of untreated patients[15]. Finally, patients with colorectal cancer who received adjuvant chemotherapy had a better 3-year survival rate than those who received

shorter courses of chemotherapy[16].

While some studies have shown that more cycles of chemotherapy leads to a better prognosis, other studies have demonstrated no effect or a worsened effect. For example, patients with ovarian cancer receiving ≥ 5 chemotherapy cycles had a poorer prognosis than patients receiving 3-4 cycles[12]. In addition, a different study conducted on patients with ovarian cancer demonstrated that additional cycles did not affect the recurrence or complete pathologic response[14]. Another study found that chemotherapy does not reduce survival in patients with inoperable stage III NSCLC. However, increased cycles (3 or more) led to more grade 3 toxicities[13].

Although it seems that increased chemotherapy cycles tends to achieve an oncologic benefit, the data is lacking for gastric cancer. Through a series of studies and analyses, the minimum number of cycles should be completed in gastric cancer patients to reduce the rate of tumor growth. During this process, the researchers found that patients who completed less than four cycles did not have a higher survival rate[17]. By analyzing the contents of previous studies, we can see that there is a certain correlation between gastric cancer recurrence and chemotherapy cycle. It was proved that > 9 cycles of chemotherapy could not reduce the recurrence rate of gastric cancer, and there was no advantage. Less than 9 cycles of chemotherapy increased the recurrence rate and reduced OS[18-19].

In the current study, the data demonstrated that ≥ 9 chemotherapy cycles did not confer any oncological benefit compared to < 9 chemotherapy cycles, indicating that ≥ 9 cycles may be considered overtreatment in stage II gastric cancer patients. Excessive chemotherapy may cause unpleasant side effects and impact the immune system, hepatic function, renal function, *etc*. However, ≥ 9 chemotherapy cycles did significantly reduce the probability of overall recurrence, local-regional metastasis, and distant metastasis rates in stage III gastric cancer patients but did not affect OS or PFS. Excessive chemotherapy cycles may have a psychological effect for patients (*i.e.* a patient may have less anxiety while being treated despite any side effects).

At present, there are some urgent problems in the research process. First of all,

this study mainly conducted retrospective analysis and focused on a single factor. Although PSM was used to reduce the bias, it was still not accurate enough. The purpose of using PSM is to conduct a simulated randomized experiment. Secondly, the chemotherapy regimen is not standardized and complete; therefore, the effects of different chemotherapy regimens were not analyzed. Nonetheless, the interaction effect between chemotherapy cycles and Lauren classification, types of gastrectomy, and maximum diameter of the tumor on OS were determined for the first time.

CONCLUSION

Overall, patients with stage II and III gastric cancer with chemotherapy cycles ≥9 have no significant effect on the prognosis of gastric cancer, so ≥9 cycles of chemotherapy are not adopted. However, in essence, ≥9 cycles of chemotherapy has a certain benefit in reducing the recurrence rate of stage III gastric cancer patients. Due to the lack of relevant data on gastric cancer and chemotherapy cycle at the present stage, it is necessary to complete the chemotherapy regimen in a more standardized way, so as to deepen the research and finally clarify the correlation between the prognosis of gastric cancer and chemotherapy cycle.

ARTICLE HIGHLIGHTS

Research background

Several studies have shown an oncological benefit with increased cycles of chemotherapy in different cancer types. However, some studies have shown no effect or a worsened effect.

Research motivation

According to a series of exploration and analysis, it is found that there is no abundant data to prove the correlation between the prognosis of gastric cancer and the duration of chemotherapy.

Research objectives

The main purpose of this study is to analyze and explore whether there is a correlation between survival rate and chemotherapy cycle in patients with stage II gastric cancer and stage III gastric cancer.

Research methods

A 1:1 ratio was used in the propensity score matching analysis to reduce the differences between groups with different chemotherapy cycles. Progression-free survival, overall survival and recurrence were components of outcome indicators.

Research results

There was no statistically significant difference in progression-free survival and overall survival between the two groups of stage II and III patients. However, overall recurrence($P < 0.001$), local-regional metastasis ($P = 0.002$), and distant metastasis (P = 0.001) in the ≥ 9 chemotherapy cycles group were significantly lower than those in the < 9 chemotherapy cycles group for stage III gastric cancer patients..

Research conclusions

For stage II and III gastric cancer patients, ≥9 cycles of chemotherapy should not be considered as far as possible, because ≥9 cycles of chemotherapy cannot effectively reduce the recurrence rate.

Research perspectives

After a series of studies, it is found that the relationship between the prognosis of gastric cancer and the chemotherapy cycle needs to be further explored to make a more abundant and standardized chemotherapy regimen.

80137-edited.docx

24%

SIMILARITY INDEX

PRIMARY SOURCES

1 www.ncbi.nlm.nih.gov
Internet
162 words — 3%

2 Masato Aragaki, Tatsuya Kato, Aki Fujiwara-Kuroda, Yasuhiro Hida, Kichizo Kaga, Satoru Wakasa. "Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study", Journal of Cardiothoracic Surgery, 2020
Crossref
69 words — 1%

3 Yifan Li, Haoliang Zhao. "Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles", Medicine, 2022
Crossref
66 words — 1%

4 fp.amegroups.cn
Internet
48 words — 1%

5 "Scientific Programme – Proffered Papers", European Journal of Cancer, 2013
Crossref
42 words — 1%

6 Kai Zhou, Anqiang Wang, Jingtao Wei, Ke Ji, Zhongwu Li, Xin Ji, Tao Fu, Ziyu Jia, Xiaojiang Wu, Ji Zhang, Zhaode Bu. "The Value of Perioperative Chemotherapy for Patients With Hepatoid Adenocarcinoma of the Stomach Undergoing Radical Gastrectomy", Frontiers in Oncology, 2022
Crossref
42 words — 1%

| 7 | bmcgastroenterol.biomedcentral.com
Internet | 41 words — 1% |
| 8 | In-Hag Song, Sukki Cho, Hee Yang, Sanghoon Jheon. "The Role of Maximum Standardized Uptake Value in PET/CT as a Prognostic Factor in Patients with Resected Esophageal Squamous Cell Carcinoma", The Thoracic and Cardiovascular Surgeon, 2014
Crossref | 39 words — 1% |
| 9 | www.jcancer.org
Internet | 34 words — 1% |
| 10 | Yun-Zi Wu, Ming Wu, Xiao-Hao Zheng, Bing-Zhi Wang, Li-Yan Xue, Shi-Kang Ding, Lin Yang, Jian-Song Ren, Yan-Tao Tian, Yi-Bin Xie. "No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer", World Journal of Gastroenterology, 2022
Crossref | 30 words — 1% |
| 11 | downloads.hindawi.com
Internet | 24 words — < 1% |
| 12 | "posters", Annals of Oncology, 06/01/2006
Crossref | 23 words — < 1% |
| 13 | ecancer.org
Internet | 22 words — < 1% |
| 14 | "ABSTRACTS", European Journal of Surgical Oncology, 200204
Crossref | 21 words — < 1% |
| 15 | Makoto Ohno, Yasuji Miyakita, Masamichi Takahashi, Shunsuke Yanagisawa, Yukie Tamura, | 21 words — < 1% |

Yoshitaka Narita. " Continuing maintenance temozolomide therapy beyond 12cycles confers no clinical benefit over discontinuation at 12cycles in patients with -wildtype glioblastoma ", Japanese Journal of Clinical Oncology, 2022
Crossref

16   www.spandidos-publications.com
Internet
20 words — < 1%

17   Zhang Liu, Zile Shen, Peng Zhang, Ge Zhu, Su Wang, Qiang Liu, Hongbo Zou, Bingwei Ma, Xialin Yan, Wangfu Zang. "Prognostic Effect of Thoracic Sarcopaenia on Short- and Long-Term Clinical Outcomes in Patients Underwent Cardiac Valve Surgery", Heart, Lung and Circulation, 2022
Crossref
17 words — < 1%

18   DAICHI WATANABE, HIRONORI FUJII, YUNAMI YAMADA, HIROTOSHI IIHARA et al. "Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin", Anticancer Research, 2019
Crossref
16 words — < 1%

19   www.mdpi.com
Internet
16 words — < 1%

20   Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Aaron M. Sargeant, Su-Peng Yeh, Li-Yuan Bai. "The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation", SpringerPlus, 2016
Crossref
15 words — < 1%

21   onlinelibrary.wiley.com
Internet
15 words — < 1%

22   www.ijrcog.org
      Internet   15 words — < 1%

23   Philip A. Philip. "Experience With Docetaxel in the   14 words — < 1%
      Treatment of Gastric Cancer", Seminars in
      Oncology, 2005
      Crossref

24   T. R. J. Evans. "A phase I and pharmacokinetic   14 words — < 1%
      study of capecitabine in combination with
      epirubicin and cisplatin in patients with inoperable oesophago-
      gastric adenocarcinoma", Annals of Oncology, 09/01/2002
      Crossref

25   "ABSTRACTS OF THE 2ND NORTH AMERICAN   13 words — < 1%
      CONGRESS OF EPIDEMIOLOGY June 21-24, 2006",
      American Journal of Epidemiology, 06/01/2006
      Crossref

26   Haibo Ma, Di Yao, Jiwei Cheng, Wei Wang,   13 words — < 1%
      Baoxing Liu, Yongkui Yu, Wenqun Xing, Jianjun
      Qin. "Older patients more likely to die from cancer-related
      diseases than younger with stage IA non-small cell lung cancer:
      a SEER database analysis", Journal of Thoracic Disease, 2021
      Crossref

27   Kai Zhu, Peng Ren, Yueyang Yang, Ying Wang,   12 words — < 1%
      Wanyi Xiao, Hongdian Zhang, Zhentao Yu. "Role
      of chemotherapy after curative esophagectomy in squamous
      cell carcinoma of the thoracic esophagus: A propensity score‐
      matched analysis", Thoracic Cancer, 2021
      Crossref

28   Matteo Ferro, Ottavio de Cobelli, Gennaro Musi,   12 words — < 1%
      Giuseppe Lucarelli et al. "Three vs. Four Cycles of
      Neoadjuvant Chemotherapy for Localized Muscle Invasive
      Bladder Cancer Undergoing Radical Cystectomy: A

Retrospective Multi-Institutional Analysis", Frontiers in Oncology, 2021
Crossref

29 ar.iiarjournals.org
Internet
12 words — < 1%

30 Andrea Bianco, Mattia Del Maestro, Andrea Fanti, Chiara Airoldi, Thomas Fleetwood, Emanuela Crobeddu, Christian Cossandi. "Use of fluorescein sodium–assisted intraoperative sample validation to maximize the diagnostic yield of stereotactic brain biopsy: progress toward a new standard of care?", Journal of Neurosurgery, 2022
Crossref
11 words — < 1%

31 Frederick O. Stephens, Karl Reinhard Aigner. "Basics of Oncology", Springer Nature, 2016
Crossref
11 words — < 1%

32 TAKASHI YOSHIOKA, MASANOBU TAKAHASHI, YASUHIRO SAKAMOTO, AKIRA OKITA et al. "Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial", Anticancer Research, 2022
Crossref
11 words — < 1%

33 Xiaohuan Tang, Mengyuan Li, Xiaolong Wu, Ting Guo et al. "Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer", OncoImmunology, 2022
Crossref
11 words — < 1%

34 pesquisa.bvsalud.org
Internet
11 words — < 1%

35 "14th World Congress of Endoscopic Surgery and 22nd International Congress of the European Association for Endoscopic Surgery (EAES) Paris, France, 25–28 June 2014", Surgical Endoscopy, 2015
Crossref

10 words — < 1%

36 "molecular markers", Annals of Oncology, 09/01/2006
Crossref

10 words — < 1%

37 Coll-Fernandez, R., R. Coll, J. F. S. Munoz-Torrero, E. Aguilar, L. Ramon Alvarez, J. C. Sahuquillo, M. Yeste, P. E. Jimenez, A. Mujal, and M. Monreal. "Supervised versus non-supervised exercise in patients with recent myocardial infarction. A propensity analysis", European Journal of Preventive Cardiology, 2015.
Crossref

10 words — < 1%

38 mafiadoc.com
Internet

10 words — < 1%

39 E. Bajetta. "Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group", Annals of Oncology, 02/20/2002
Crossref

9 words — < 1%

40 Karl Gunnar Janunger, Larsolof Hafs. "A Systematic Overview of Chemotherapy Effects in Gastric Cancer", Acta Oncologica, 2009
Crossref

9 words — < 1%

41 Keijiro Sugimura, Hiroshi Miyata, Koji Tanaka, Tomoki Makino et al. "Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in

9 words — < 1%

Patients With Clinical T4b Esophageal Cancer", Annals of Surgery, 2021

Crossref

---

42 Song Xiao, Xiangpeng Zhan, Tao Chen, Jingxin Wu et al. "Prognostic values of distal ureter involvement and survival outcomes in bladder cancer at T1 and T2 stages: a propensity score matching study", International Urology and Nephrology, 2022

Crossref

9 words — < 1%

---

43 Takeuchi, K.. "Total Gastrectomy with Distal Pancreatectomy and Splenectomy for Advanced Gastric Cancer", Journal of Surgical Research, 200112

Crossref

9 words — < 1%

---

44 Takuro Ogata, Keijiro Araki, Kimio Matsuura, Michiya Kobayashi, Taisuke Inomata, Ogawa Yasuhiro, Shoji Yoshida. "A 10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients", International Journal of Radiation Oncology*Biology*Physics, 1995

Crossref

9 words — < 1%

---

45 corejournals.info
Internet

9 words — < 1%

---

46 researchers.general.hokudai.ac.jp
Internet

9 words — < 1%

---

47 www.jultrasoundmed.org
Internet

9 words — < 1%

---

48 www.nice.org.uk
Internet

9 words — < 1%

49 Ahmet Namazov, Limor Helpman, Ram Eitan, Zvi Vaknin et al. "The diagnosis of endometrial cancer in women with asymptomatic endometrial polyp does not increase survival rates: an israel gynecologic oncology group study", Maturitas, 2021
Crossref
8 words — < 1%

50 Shohei Koyama, Azusa Ozaki, Yoji Iwasaki, Takao Sakita et al. "Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma", Cancer Immunology Immunotherapy, 1986
Crossref
8 words — < 1%

51 health.yahoo.com
Internet
8 words — < 1%

52 tessera.spandidos-publications.com
Internet
8 words — < 1%

53 wjso.biomedcentral.com
Internet
8 words — < 1%

54 www.cureus.com
Internet
8 words — < 1%

55 www.researchgate.net
Internet
8 words — < 1%

56 "abstracts", International Journal of Gynecological Cancer, 9/2004
Crossref
6 words — < 1%

57 Antonino Grassadonia, Antonella De Luca, Erminia Carletti, Patrizia Vici et al. "Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer", Cancers, 2022
Crossref
6 words — < 1%

58 Georgina V Long, Reinhard Dummer, Omid Hamid, Thomas F Gajewski et al. "Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study", The Lancet Oncology, 2019
Crossref

6 words — < 1%

59 Kyoji Ogoshi. "Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer", Cancer Immunology Immunotherapy, 05/1992
Crossref

6 words — < 1%

| EXCLUDE QUOTES | OFF | | EXCLUDE SOURCES | OFF |
| EXCLUDE BIBLIOGRAPHY | OFF | | EXCLUDE MATCHES | OFF |